Carlsmed announced today that it raised $52.5 million in a Series C funding round co-led by B Capital and U.S. Venture Partners.
The Carlsbad, California-based AI-enabled personalized surgery company plans to use the funds to accelerate commercialization efforts. It wants to boost the commercialization of its aprevo personalized spine surgery platform for lumbar fusion procedures, in particular.
Related: X-Therma raises $22.4m to scale cryopreservation devices
The company also hopes to put the funds toward developing aprevo for cervical fusions. Carlsmed plans to launch that offering in 2025.
Carlsmed already holds FDA breakthrough device designation for the aprevo lumbar and cervical patient-specific interbody fusion devices. Its implantable devices and software platforms hold FDA clearance for lumbar spine fusion. That includes in anterior, lateral and transforaminal approaches.
Dr. Robert Mittendorff, general partner and head of healthcare at B Capital, said in a news release that Carlsmed is “transforming spine surgery.” He said that the application of its AI-enabled technology helped it become a “category creator in a market overdue for meaningful innovation.”
Mittendorf said he expects personalized surgery to become the standard of care in the spine market.
“We started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevo patient-specific implants are achieving this goal,” said Mike Cordonnier, CEO of Carlsmed. “Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients.”
